Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Inclusion Criteria: * Patients aged 35 years or older, diagnosed with Type 2 Diabetes Mellitus, * Specifically, individuals with a documented HbA1c level equal to or exceeding 8.5% over the course of the last six months or more are considered eligible candidates. * these patients should currently be undergoing treatment involving a combination of Insulin and either Metformin or Sitagliptin. Exclusion Criteria: * Patients with a history of recurrent urinary tract infections * those who are currently pregnant are excluded from participation in the study. * patients with an estimated Glomerular Filtration Rate (eGFR) exceeding 40 ml/min/1.73m², * Furthermore, individuals with other concurrent medical conditions, and those who are unable to provide informed consent for the study, have also been excluded.